Why ANI Pharmaceuticals Inc. Stock Roared Higher

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of ANI Pharmaceuticals (NASDAQ: ANIP  ) , a specialty developer of branded and generic drugs, roared higher by as much as 11% after the company announced the acquisition of the drug Lithobid from Noven Therapeutics.

So what: According to ANI Pharmaceuticals' midday press release, total consideration paid for the extended release tablets, which treat manic episodes of bipolar disorder, was $12 million. This includes an $11 million up-front payment from ANI to Noven, as well as $1 million in future sales milestone payments. ANI anticipates launching Lithobid this month under its own label, with the purchase expected to annually add $4 million in revenue and $3.9 million in adjusted EBITDA. As ANI's president and CEO pointed out, "Prior to the acquisition, ANI contract manufactured Lithobid, which allows us to immediately launch ANI-labeled product."

Now what: ANI said the magic words in its press release: "immediately accretive" to earnings. ANI has largely developed its generic portfolio through internal discoveries, but it made waves recently with two mature drug purchases, including today's buy. In December, it acquired 31 generic drugs from Teva Pharmaceutical for $12.5 million and a percentage of gross profits from future product sales. ANI's ability to supplement its high-margin branded portfolio with both internal and external generic drugs makes me believe that it has the potential to head even higher over the long term.

ANI may have soared today, but the enormous potential from this revolutionary product could leave ANI in the dust! 
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3015016, ~/Articles/ArticleHandler.aspx, 9/18/2014 1:58:50 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement